TGA designates new orphan drug
This article was originally published in Scrip
Executive Summary
Australia's Therapeutics Goods Administration (TGA) has designated a new orphan drug: Janssen-Cilag's (Johnson & Johnson) Prezista (darunavir) in doses of 75mg, 150mg, 300mg and 600mg, for the treatment of HIV infection in paediatric patients aged six to 18 years of age. It received designated status on August 22nd.